LS Investment Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.22M Sell
50,485
-11,618
-19% -$304K 0.16% 80
2026
Q1
$1.74M Sell
62,103
-7,218
-10% -$192K 0.26% 57
2025
Q4
$1.73M Sell
69,321
-12,838
-16% -$324K 0.24% 58
2025
Q3
$2.09M Sell
82,159
-8,020
-9% -$198K 0.29% 52
2025
Q2
$2.19M Buy
90,179
+9,727
+12% +$227K 0.32% 51
2025
Q1
$2.04M Sell
80,452
-14,560
-15% -$381K 0.31% 52
2024
Q4
$2.52M Sell
95,012
-42,404
-31% -$1.15M 0.37% 50
2024
Q3
$3.98M Sell
137,416
-1,108
-0.8% -$32.3K 0.59% 41
2024
Q2
$3.88M Buy
138,524
+12,442
+10% +$343K 0.6% 41
2024
Q1
$3.5M Sell
126,082
-7,493
-6% -$208K 0.56% 43
2023
Q4
$3.85M Buy
133,575
+1,386
+1% +$41.9K 0.67% 38
2023
Q3
$4.38M Sell
132,189
-15,281
-10% -$540K 0.82% 38
2023
Q2
$5.41M Sell
147,470
-33,707
-19% -$1.31M 0.95% 39
2023
Q1
$7.39M Sell
181,177
-25,871
-12% -$1.12M 1.37% 29
2022
Q4
$10.6M Sell
207,048
-14,015
-6% -$672K 2.07% 13
2022
Q3
$9.67M Buy
221,063
+6,931
+3% +$337K 1.96% 17
2022
Q2
$11.2M Buy
214,132
+400
+0.2% +$20.4K 2.09% 11
2022
Q1
$11.1M Sell
213,732
-2,265
-1% -$118K 1.76% 22
2021
Q4
$12.8M Sell
215,997
-47,137
-18% -$2.34M 1.92% 18
2021
Q3
$11.3M Buy
263,134
+2,557
+1% +$113K 1.46% 29
2021
Q2
$10.2M Sell
260,577
-114,097
-30% -$4.44M 1.29% 29
2021
Q1
$13.6M Sell
374,674
-21,483
-5% -$763K 0.76% 28
2020
Q4
$14.6M Sell
396,157
-31,924
-7% -$1.17M 0.77% 24
2020
Q3
$14.9M Buy
428,081
+7,599
+2% +$266K 0.85% 21
2020
Q2
$13M Buy
420,482
+73,841
+21% +$2.51M 0.81% 22
2020
Q1
$10.7M Sell
346,641
-7,910
-2% -$270K 0.78% 26
2019
Q4
$13.2M Buy
354,551
+956
+0.3% +$34.1K 0.71% 30
2019
Q3
$12.1M Sell
353,595
-19,298
-5% -$702K 0.7% 29
2019
Q2
$15.3M Sell
372,893
-3,005
-0.8% -$119K 0.93% 18
2019
Q1
$15.1M Sell
375,898
-8,524
-2% -$341K 0.94% 17
2018
Q4
$15.9M Sell
384,422
-60,042
-14% -$2.49M 1.11% 10
2018
Q3
$18.6M Sell
444,464
-10,857
-2% -$418K 1.07% 11
2018
Q2
$15.7M Sell
455,321
-6,481
-1% -$221K 0.95% 18
2018
Q1
$15.6M Sell
461,802
-1,262
-0.3% -$43.4K 0.93% 23
2017
Q4
$15.9M Sell
463,064
-11,309
-2% -$386K 0.93% 20
2017
Q3
$16.1M Sell
474,373
-14,436
-3% -$464K 0.96% 20
2017
Q2
$15.6M Buy
488,809
+40,415
+9% +$1.27M 0.95% 21
2017
Q1
$14.6M Sell
448,394
-40,423
-8% -$1.27M 0.93% 20
2016
Q4
$15.1M Buy
488,817
+7,293
+2% +$223K 1.06% 15
2016
Q3
$15.5M Buy
481,524
+25,580
+6% +$855K 1.14% 16
2016
Q2
$15.2M Sell
455,944
-31,515
-6% -$1.01M 1.05% 17
2016
Q1
$13.7M Buy
487,459
+4,816
+1% +$138K 1.02% 17
2015
Q4
$14.8M Sell
482,643
-48,278
-9% -$1.52M 1.15% 13
2015
Q3
$15.8M Buy
530,921
+6,515
+1% +$209K 1.27% 12
2015
Q2
$16.7M Buy
524,406
+8,846
+2% +$288K 1.24% 14
2015
Q1
$17M Buy
515,560
+76,901
+18% +$2.44M 1.3% 12
2014
Q4
$13M Buy
438,659
+1,632
+0.4% +$46.8K 1.05% 24
2014
Q3
$12.3M Sell
437,027
-36,304
-8% -$1.02M 1.05% 26
2014
Q2
$13.3M Sell
473,331
-97,204
-17% -$2.77M 1.13% 20
2014
Q1
$17.4M Sell
570,535
-17,237
-3% -$514K 1.42% 12
2013
Q4
$17.1M Buy
587,772
+24,003
+4% +$699K 1.54% 11
2013
Q3
$15.4M Sell
563,769
-10,143
-2% -$276K 1.85% 8
2013
Q2
$15.3M Buy
+573,912
New +$15.9M 1.96% 7

Other funds holding PFE

LS Investment Advisors's PFE Position: Q2 2026 in Review

LS Investment Advisors reduced its Pfizer (PFE) stake by 19% in Q2 2026, selling an estimated $304K and leaving 50,485 shares worth $1.22M. The position accounts for 0.16% of the portfolio, ranked #80.

LS Investment Advisors first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $18.6M in Q3 2018. 680 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • LS Investment Advisors held 50,485 shares of Pfizer worth $1.22M as of Q2 2026.
  • LS Investment Advisors sold 11,618 Pfizer shares in Q2 2026, an estimated $304K.
  • Pfizer made up 0.16% of LS Investment Advisors's portfolio in Q2 2026, its #80 holding.
  • LS Investment Advisors first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • LS Investment Advisors's Pfizer position peaked at $18.6M in Q3 2018.
  • 680 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on LS Investment Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.